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A B S T R A C T
Hypothalamus-pituitary-thyroid (HPT) axis dysfunction has been associated with pathophysiology of major depres-
sion. The aim of the study was to determine serum levels of total 3,5,3’-triiodothyronine (T3), total thyroxine (T4) and
thyroid-stimulating-hormone (TSH) in patients with major depression and healthy controls. The study included 53
medication-free patients with depression and 49 healthy controls. Exclusion criteria for patients was: other axis-I and
axis-II diagnoses, intensive psychotherapy or electroconvulsive therapy, prior clinical and/or laboratory evidence of hypo-
or hyperthyroidism, alcohol or nicotine dependence, pregnancy, hormone supplement therapy, somatic illnesses (diabe-
tes, renal or hepatic disorders), infections or autoimmune diseases, recent surgical treatment or significantly changed
body weight. For controls: the presence of psychiatric disorders and/or thyroid dysfunctions. The diagnosis of major de-
pression was made using structured clinical interview based on DSM-IV criteria. The results showed significantly lower
T3 and TSH levels in patients compared to controls. There was no significant difference in T4 values between patients
with depression and control subjects. The results showing altered levels of thyroid hormones in depression indicate that
further research on thyroid hormone activity can contribute to the better understanding of the biological basis of depres-
sion. Based on the high frequency of the subtle neuroendocrine disorders coexisting with depression, the association of
thyroid abnormalities and depression should not be underestimated. Future research should identify different behav-
ioral endophenotypes characteristic for depression, which would greatly facilitate delineating the biological phenomena
associated with this psychiatric illness.
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Introduction
Thyroid hormones (3,5,3’-triiodothyronine /T3/, thy-
roxine /T4/ and thyroid-stimulating-hormone /TSH/) reg-
ulate development, metabolism and function of many or-
gans. They exert a multitude effects on the central ner-
vous system including modulation of gene expression1,
action on membrane-bound receptors and second-mes-
sengers2, neurotransmission3 and promotion of the neu-
rogenesis in adult brain4. Based on the results of the se-
lective uptake of the labeled T3 in synaptosomes, and
localization of specific T3 receptors on the synaptic mem-
brane, it has been postulated that T3 could act as a neu-
rotransmitter in the brain5.
Numerous multidisciplinary studies documented a
high prevalence of mood disorders, and particularly de-
pression, among patients with thyroid dysfunction. Al-
though the role of T3, T4 and TSH in the pathophysio-
logy of mental disorders is not clear, it has been sug-
gested that small changes of thyroid hormone levels,
even within the normal range, might be related with the
altered brain function in depression6, schizophrenia7,
and posttraumatic stress disorder8. There is a strong pos-
sibility that the etiology and treatment outcome of de-
pression could be related to the thyroid status. Litera-
ture data on the plasma hormone values in patients with
depression are controversial. An increase9 and a decrea-
se10 in plasma TSH levels, a decrease in T311 or both T3
and TSH12 or increase in T4 and TSH with no change in
T3 levels13 were observed in patients with depression
compared to healthy controls.
In order to contribute to the better understanding of
the relationship between thyroid activity and depression,
we conducted a preliminary study in which we assessed
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the thyroid function by measuring serum total T3, total
T4 and TSH levels in patients with major depression
with no prior history of thyroid-related illnesses and in
healthy controls.
Methods
The study included 43 (30 female, 13 male) nonsui-
cidal and nonpsychotic patients with depression (mean
age  SD, 48  11.9 years). The diagnosis of major depres-
sion was made using structured clinical interview based
on DSM-IV criteria14. All patients had a minimum total
score of 21 on the Montgomery-Asberg Depression Rat-
ing Scale15. Patients were in stable medical condition.
Exclusion criteria were: other axis-I and axis-II diagno-
ses, intensive psychotherapy or electroconvulsive ther-
apy, prior clinical and/or laboratory evidence of hypo- or
hyperthyroidism, alcohol or nicotine dependence, soma-
tic illnesses (diabetes, renal or hepatic disorders), infec-
tions or autoimmune diseases, recent surgical treatment
or significantly changed body weight. Pregnant or lactat-
ing female subjects or those taking estrogen therapy and
contraceptives were not included in the study. Control
group consisted of 59 (41 female, 18 male) healthy con-
trol subjects (mean age 52  8.0 years) with no psychiat-
ric disorders and thyroid dysfunctions. All subjects were
medication free for at least 8 days prior to blood sam-
pling. Written informed consent was obtained from all
participants. The study was approved by the Local Ethics
Committee and was performed in accordance with Decla-
ration of Helsinki.
Blood sampling was always done at 8:00 a.m (to avoid
the influence of circadian rhythm), after an overnight
fasting. In patients blood samples were taken before
their admission at hospital. Serum levels of total T3, to-
tal T4 and TSH were determined with commercially
available radioimmunoassay (RIA) kits and time-resol-
ved fluoroimmunoassay (Delfia) with the kits from Per-
kin-Elmer, USA. The normality ranges were as follows:
T3: 1.3–2.5 nmol/L; T4: 69–145 nmol/L; TSH: 0.3–4.0
mU/L). Intra- and inter-assay variation coefficients were
2.5% for T3, 3.6% for T4 and 3.5% for TSH.
Data are presented as mean  SD. Statistical evalua-
tion of the data (means  SD) was done using Mann-
Whitney test. All calculations were made using statistical
program SigmaStat (Jandel, version 3.1, Jandel, USA)
Results
A significant difference in T3 and TSH levels was ob-
served among groups (Figure 1). Patients with depres-
sion had significantly lower T3 (T43,59=331.0, P=0.026,
Mann-Whitney test) and TSH (T43,59=1772.0, P=0.004,
Mann-Whitney test) levels than healthy controls. There
was no significant (T43,59=221.5, P=0.847, Mann-Whit-
ney test) difference in T4 values between patients with
depression (111.2  27.8 nmol/L) and controls (112.6 
19.1 nmol/L). Although altered (T3, TSH) and unaltered
(T4) hormone values were observed in patients as com-
pared to healthy controls, mean hormone values in both
groups were within the normal range.
Discussion
The results of the present study confirm the presump-
tion that major depression might be associated with al-
tered levels of thyroid hormones. Our results of lower to-
tal T3 and TSH levels in patients with depression are in
agreement with previous data10,12, but are in contrast
with the reports of the unaltered or increased secretion
of thyroid hormones in patients with depression9. The
difference between studies might be due to a small num-
ber of participants and inadequate exclusion criteria.
Various factors influence thyroid hormone levels like
stress, malnutrition, smoking, circadian variation, sleep
deprivation, alcoholism, pregnancy, aging, thyroid medi-
cations, other medications (lithium, corticosteroids, phe-
nytoin, salicylates, furosemide, propranolol, amiodarone)
and concomitant clinical disease, which greatly compli-
cates the designs of the possible studies with thyroid hor-
mones.
Although depression is clearly not caused by the thy-
roid dysfunction and patients are generally viewed as
euthyroid, many patients with depression show subtle al-
terations in thyroid function as a consequence of altered
hypothalamus-pituitary-thyroid axis (HPT) activity16.
Results of our study, showing lower T3 and TSH (but still
within normal range) in patients with depression, resem-
ble euthyroid sick syndrome, related to abnormalities in
thyroid function occurring often in patients with non-
thyroidal illnesses17. It is manifested with normal, low or
high serum TSH occurring in conjunction with normal or
low total T4 and low total T3 levels, that generally return
to normal values with successful treatment of the pri-
mary disease.
The alterations in thyroid function in depression
might be due to decreased T4 to T3 conversion, alter-
ations in serum thyroid hormone binding proteins, de-
creased concentration of TSH or its effect on the thyroid.




































Fig. 1. (A) Serum levels of the T3 and (B) serum levels of the TSH
in depressed patients and healthy controls. Each column repre-
sents mean  SD. Number of subjects is given in parenthesis.
*P=0.026 vs. healthy controls; **P=0.004 vs. healthy controls
(Mann-Whitney test).
Cytokines, free fatty acid, cortisol and glucagon have also
been studied as possible mediators of thyroid func-
tion18–19. Sub-clinical thyroid dysfunction may constitute
an expression of a coordinated neuroendocrine-immune
response to nonthyroidal disorder20.
The alterations in T3 levels could have an important
role in the stress induced atrophy and death of neu-
rons21, which is related to pathophysiology and treat-
ment of depression. T3 promoted neurogenesis in brains
of developing and mature rats22, while thyroid hormone
deficiency reduced growth and the number of cells in the
dentate gyrus and induced abnormal neuronal migration
and maturation in adult rats23. In addition, hypothyroid
animals displayed a depressive-like behavior, suggesting
that subclinical hypothyroidism may lower the threshold
for the occurrence of depression24.
In clinical trials, co-administration of T3 with antide-
pressants improved the treatment response in major25
and non-refractory depression26. Pathophysiology of de-
pression is associated with a higher sensitivity of beta-
-adrenergic receptors, inhibition of the deiodinase, and
concomitant decrease in brain T3 and serotonin levels27.
Mode of action of various antidepressants including se-
lective serotonin reuptake inhibitors (SSRIs) involves
the stimulation of type II deiodinase in the rat brain,
with no effect on type III deiodinase28. These effects lead
to the increased cerebral T3 concentrations and increa-
sed serotonergic neurotransmission. Recently, Lifschytz
et al.29 found also that T3, alone and in combination with
the SSRI fluoxetine, reduced mRNA transcription for the
somatodendritic 5-HT1A and nerve terminal 5-HT1B
autoreceptors.
Alterations in the HPT axis in non-treated depression
could be related and/or partially explained by serotonin
and/or noradrenalin brain alterations in depression. The
role of T3 in serotonergic and the noradrenergic systems
has been acknowledged, thus confirming the close rela-
tion between the thyroid activity and depressive disor-
ders. Current models of etiology of depression propose
that reduced hippocampal neurogenesis is likely associ-
ated with excess adrenal steroid and cytokine secretion,
with consequent reductions in neurotrophic factors, such
as brain derived neurotrophic factor (BDNF)30.
Conclusions
Since thyroid hormones are important regulators of
HPT axis, and many of their complex actions have been
demonstrated, like interactions with neurotransmitters,
enhancement of neuronal plasticity, stimulation of
hippocampal neurogenesis, and influence on the expres-
sion of various neurotrophins including BDNF4,31, fur-
ther research on thyroid hormone activity can contribute
to the better understanding of the biological basis of de-
pression. Moreover, based on the high frequency of the
subtle neuroendocrine disorders and, coexisting with de-
pression, the association of thyroid abnormalities and de-
pression should not be underestimated. With the use of
thyroid function tests, future research should identify
different behavioral endophenotypes characteristic for
depression, which would greatly facilitate delineating the
biological phenomena associated with this psychiatric ill-
ness.
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NASLOV HRV?????????????????????
S A @ E T A K
Patofiziologija depresije se povezuje izme|u ostaloga i s poreme}enom funkcijom osovine hipotalamus-hipofiza-
-{titna `lijezda. Cilj ovog istra`ivanja bio je odrediti koncentraciju hormona {titnja~e: ukupnog trijodtironina (T3),
ukupnog tiroksina (T4) i tireotropin-stimuliraju}eg-hormona (TSH) u bolesnika s velikim depresivnim poreme}ajem i
usporediti ih s vrijednostima u zdravih osoba. Ispitanici su bili 53 bolesnika s depresijom i 49 zdravih osoba, starijih od
18 godina. Dijagnoza velikog depresivnog poreme}aja je postavljena primjenom strukturiranog klini~kog intervjua
prema DSM-IV kriterijima. Bolesnici su imali najmanje 21 bod na Montgomery-Asberg ocjenskoj ljestvici za depresiju.
U kontrolnu skupinu ispitanika uklju~ene su zdrave osobe, koje nisu uzimale lijekove, te koje u obitelji nemaju du{ev-
nih bolesnika. Iz istra`ivanja su isklju~ene osobe kod kojih je bila prisutna zlouporaba psihoaktivnih tvari i alkohola,
osobe sa somatskim bolestima (dijabetes, bolesti bubrega, jetre), i osobe ~iji prethodni klini~ki ili laboratorijski nalazi
upu}uju na hipo ili hipertireozu. Rezultati su pokazali statisti~ki zna~ajno sni`enu koncentraciju T3 i TSH u bolesnika
u usporedbi s vrijednostima hormona {titnja~e u zdravih osoba. Koncentracija T4 bila je podjednaka u depresivnih
bolesnika i zdravih osoba. Rezultati upu}uju na promjene koncentracija hormona {titnja~e u depresivnih bolesnika,
koje ne bi trebalo zanemariti. Nastavak istra`ivanja razli~itih endofenotipova karakteristi~nih za depresivni poreme}aj
trebao bi pridonijeti razja{njenju etiologije i biolo{ke podloge depresije.
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